FDA warns company marketing unapproved CBD products

FDA said Tuesday it has issued a warning letter to Curaleaf Inc., of Wakefield, MA, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat conditions including Alzheimer disease, opioid withdrawal, and pet anxiety. Acting FDA Commissioner Ned Sharpless, MD, noted: "Today's action demonstrates that the agency stands firm in its commitment to continue monitoring the marketplace and protecting the public health by taking action as needed against companies that deceive consumers and put them at risk by illegally selling products marketed for therapeutic uses for which they are not approved, such as those claiming to treat cancer or Alzheimer disease. Consumers should beware of purchasing or using any such products." According to FDA, Curaleaf used webpages, an online store, and social media sites to make unfounded claims about more than 12 different. Curaleaf has 15 days to respond to the agency with plans on how the violations will be corrected.

Read More